Mercator, Pepscan enter multi-program cancer research collaboration

Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration. The companies will collaborate to optimize Mercator's 'Homing Peptides' using Pepscan's proprietary CLIPS technology.

“Pepscan's approach to peptide optimization is unique, systematic, fast, and efficient, and it provides Mercator with an opportunity to rapidly move its peptide-drug conjugates (PDCs) into development.”

Mercator's Homing Peptides are discovered through a unique in vivo screening process, including screening in consenting end-stage cancer patients. These peptides have been demonstrated in vivo to bind to receptors that are highly expressed on human tumors and induce internalization of both the peptide and the receptor. Pepscan's CLIPS technology will be applied to improve the potency and stability of peptides by locking the peptides into the biologically active conformation.

Dr. Roy Lobb, Chairman & CSO of Mercator, commented, "Pepscan's approach to peptide optimization is unique, systematic, fast, and efficient, and it provides Mercator with an opportunity to rapidly move its peptide-drug conjugates (PDCs) into development."

Under the terms of the Research and License Agreement between Mercator and Pepscan, Pepscan will increase the potency and stability of Mercator's Homing Peptides and license to Mercator the associated intellectual property rights. Mercator will pay Pepscan undisclosed research funding, milestones, and royalties in connection with the development of optimized Homing Peptides and the development and commercialization of PDC products that couple optimized Homing Peptides with tumor-killing payloads.

"Mercator is in a unique position to make a big difference in cancer treatment," said Dr. Wim Mol, CEO of Pepscan. "The Pepscan team is excited to work with Mercator on designing and building optimized targeting moieties for Mercator's PDCs. We see the promise of Mercator's technology, and we are pleased to help Mercator achieve that promise."

Source:

 Mercator Therapeutics and Pepscan Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients